Corporate
-
Research & Development
Natco Pharma to cash in on R&D successes
Our Bureau
Hyderabad
,
Oct. 1
NATCO Pharma Ltd (NPL), the city-based pharmaceutical company known for its time-release technology, has drawn up a strategy of cashing in on the successes recorded by its research and development (R&D) wing and to tap the regulated markets.
Addressing the annual general meeting here, the NPL Chairman and Managing Director, Dr V.C. Nannapaneni, informed the shareholders that the research based upon molecular modelling techniques initiated by the company during the past two years has already resulted in synthesising 20 lead compounds. These were primarily in the fields of anti-cancer, anti-ulcer and anti-depressant segments.
According to Dr Nannapaneni, these compounds were currently in the process of screening and would await pre-clinical trials. Further, the company's efforts in biotechnology were beginning to bear fruits with one molecule based on RDNA technology coming off the lab and advancing into pre-clinical trials and one specialised product based on peptide synthesis about to complete the lab work next only to the innovator and also one fermentation based drug for use in organ transplant also coming through the lab.
Article
E-Mail
::
Comment
::
Syndication
|
